{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:35:34Z","timestamp":1777433734424,"version":"3.51.4"},"reference-count":13,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Australas Psychiatry"],"published-print":{"date-parts":[[2023,10]]},"abstract":"\n Objective<\/jats:title>\n The aim is to assess the impact of long-acting buprenorphine (LAI-BNP) on frequency of methamphetamine (MA) use.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We undertook an observational, descriptive, retrospective cohort study of patients of a public, tertiary, community-based Alcohol and Other Drug Service (AODS) with opioid use disorder (OUD) treated with LAI-BNP who are current or past users of MA. We assessed the changes of frequency of use in their MA use at start (baseline), 3 and 6\u00a0months of LAI-BNP.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Study included 59 participants. Based on their MA use at the commencement of LAI-BNP, the sample was further sub-grouped as active users ( n = 30) and past users ( n = 29). At 6\u00a0months of LAI-BNP, all the past users remained abstinent from MA use. 70% ( n = 21) of participants with active MA use had reduced or ceased their MA use while 17% ( n = 5) increased their MA use at 6\u00a0months.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The results favour the use of LAI-BNP as a potential treatment for MA use.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/10398562231190211","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T14:14:26Z","timestamp":1689948866000},"page":"690-693","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of long-acting buprenorphine injection on methamphetamine use: A retrospective cohort study"],"prefix":"10.1177","volume":"31","author":[{"given":"M","family":"Raza","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Gold Coast University Hospital, Gold Coast, QLD, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7633-7601","authenticated-orcid":false,"given":"H","family":"Abeysundera","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Gold Coast University Hospital, Gold Coast, QLD, Australia; and School of Medicine, Griffith University, Gold Coast, QLD, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Branjerdporn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Gold Coast University Hospital, Gold Coast, QLD, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"bibr1-10398562231190211","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00711-x"},{"key":"bibr2-10398562231190211","volume-title":"United Nations World Drug Report 2019"},{"key":"bibr3-10398562231190211","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)322305"},{"key":"bibr4-10398562231190211","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0000000000000168"},{"key":"bibr5-10398562231190211","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2010.09.003"},{"key":"bibr6-10398562231190211","unstructured":"Insight- understanding methamphetamine, https:\/\/insight.qld.edu.au\/training\/meth-the-basics\/detail (2022)."},{"key":"bibr7-10398562231190211","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.10.005"},{"key":"bibr8-10398562231190211","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3554-6"},{"key":"bibr9-10398562231190211","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-2007-3"},{"key":"bibr10-10398562231190211","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001320"},{"key":"bibr11-10398562231190211","unstructured":"Long-acting injection buprenorphine in the treatment of opioid dependence In: Health Q (ed.). Queensland2019 https:\/\/www.health.qld.gov.au\/__data\/assets\/pdf_file\/0032\/932684\/lai-bpn-clinical-guidelines.pdf, (accessed 09.08.2022)."},{"key":"bibr12-10398562231190211","unstructured":"Lumivero XL-STAT https:\/\/www.xlstat.com\/en\/ (2023), (accessed 09 08 2022)."},{"key":"bibr13-10398562231190211","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.83"}],"container-title":["Australasian Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10398562231190211","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10398562231190211","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10398562231190211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:52:11Z","timestamp":1777377131000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10398562231190211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1177\/10398562231190211"],"URL":"https:\/\/doi.org\/10.1177\/10398562231190211","relation":{},"ISSN":["1039-8562","1440-1665"],"issn-type":[{"value":"1039-8562","type":"print"},{"value":"1440-1665","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]}}}